Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Luminex, Myriad boasts top line growth, but Affymetrix sinks

This article was originally published in Clinica

Executive Summary

Luminex, the developer of the xMAP multi-analyte profiling platform, has forecast a bullish revenue outlook for 2009, after it recorded robust top line growth for 2008, respectively. Describing 2008 as a "transformational year", the Austin, Texas firm said fourth-quarter revenue was up 31% to $28.3m. Growth during this period reflected an 18% rise in shipments of its analyser systems, as well as a 53% increase in consumable sales and 44% increase in royalty revenue. Gross profit margin also showed considerable improvement, widening 7 percentage points in the fourth quarter to 69%. However, reported net income plunged nearly 82% to $2m in 2008, due to the negative impact of one-off gains in the previous year that boosted earnings for Q4 2007. Excluding the gain on settlement of litigation and liability, Luminex had recorded a loss of $2.8m for Q4 2007, which meant it swung into profit for the same period in 2008. For the full year 2008, revenue was up 39% at $104.4m, gross profit margin increased from 61% to 68% and net income was $3.1m. Luminex anticipates maintaining double-digit growth rates for 2009. It expects full year revenue to grow between 25-34% to $130-140m.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

MT042818

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel